Li Q - Search Results

1

Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.

Liao H, Liu Y, Li X, Wang J, Chen X, Zou J, Li Q, Liu L, Wang J, Huang B, Lu F, Xu D. Liao H, et al. Among authors: li x, li q. Antivir Ther. 2019;24(2):105-115. doi: 10.3851/IMP3280. Antivir Ther. 2019. PMID: 30511941

2

Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients.

Liu L, Liu Y, Chen R, Li X, Luo D, Zhao Y, Li Q, Huang B, Wang FS, Liu X, Xu D. Liu L, et al. Among authors: li x, li q. Antiviral Res. 2019 Apr;164:131-138. doi: 10.1016/j.antiviral.2019.02.012. Epub 2019 Feb 20. Antiviral Res. 2019. PMID: 30796932

3

Molecular cloning and phenotypic analysis of drug-resistance mutants with relevant S-region variants of HBV for a patient during 189-month anti-HBV treatment.

Liu Y, Wu C, Chen R, Li X, Xu Z, Li Q, Li L, Wang FS, Yang D, Lu M, Xu D. Liu Y, et al. Among authors: li x, li l, li q. Antivir Ther. 2019;24(4):237-246. doi: 10.3851/IMP3305. Antivir Ther. 2019. PMID: 30882363

4

Correction: Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.

Liao H, Liu Y, Li X, Wang J, Chen X, Zou J, Li Q, Liu L, Wang J, Huang B, Lu F, Xu D. Liao H, et al. Among authors: li x, li q. Antivir Ther. 2019;24(2):151. doi: 10.3851/IMP3314. Antivir Ther. 2019. PMID: 31050658 No abstract available.

5

Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment.

Luo D, Liu Y, Chen R, Niu M, Liu L, Li X, Li Q, Huang B, Wang J, Xu D, Lin S. Luo D, et al. Among authors: li x, li q. Antiviral Res. 2019 Oct;170:104579. doi: 10.1016/j.antiviral.2019.104579. Epub 2019 Aug 6. Antiviral Res. 2019. PMID: 31398372

6

Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.

Zhao L, Li X, Cheng Y, Chen R, Shao J, Zhou Y, Li Q, Liao H, Zhao Y, Liu L, Su H, Liu Y, Liu Y, Xu D. Zhao L, et al. Among authors: li x, li q. Antiviral Res. 2018 Jun;154:26-34. doi: 10.1016/j.antiviral.2018.04.003. Epub 2018 Apr 6. Antiviral Res. 2018. PMID: 29630974

7

Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection.

Zhang K, Liu Y, Chen R, Li Q, Xu Z, Si L, Cheng Y, Yang Y, Chen J, Xu D, Lin S. Zhang K, et al. Among authors: li q. J Med Virol. 2018 Feb;90(2):263-270. doi: 10.1002/jmv.24936. Epub 2017 Sep 22. J Med Virol. 2018. PMID: 28876463

8

Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation.

Li H, Xia Q, Zeng B, Li ST, Liu H, Li Q, Li J, Yang SY, Dong XJ, Gao T, Munker S, Liu Y, Liebe R, Xue F, Li QG, Chen XS, Liu Q, Zeng H, Wang JY, Xie Q, Meng QH, Wang JF, Mertens PR, Lammert F, Singer MV, Dooley S, Ebert MP, Qiu DK, Wang TL, Weng HL. Li H, et al. Among authors: li j, li st, li qg, li q. J Hepatol. 2015 Jul;63(1):50-9. doi: 10.1016/j.jhep.2015.01.029. Epub 2015 Jan 31. J Hepatol. 2015. PMID: 25646889

9

Long-term antifibrotic action of interferon-γ treatment in patients with chronic hepatitis B virus infection.

Wu YJ, Cai WM, Li Q, Liu Y, Shen H, Mertens PR, Dooley S, Weng HL. Wu YJ, et al. Among authors: li q. Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):151-7. doi: 10.1016/s1499-3872(11)60024-6. Hepatobiliary Pancreat Dis Int. 2011. PMID: 21459721

10

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: li x. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65,587 results

Search Page

Filters